AI Analysis | Feedback

Aquestive Therapeutics is like the Keurig for prescription drugs, focused on creating convenient, specialized 'pods' (oral films) for delivering medicine instead of traditional pills or injections.

Consider them a pharmaceutical 'material science' innovator, much like 3M applies its expertise to various products, but Aquestive specifically develops thin oral films to make taking important medications easier and more effective.

They are similar to Noven Pharmaceuticals, but instead of specialized transdermal patches, Aquestive focuses on pioneering oral film formulations for drug delivery.

AI Analysis | Feedback

• Sympazan: An oral soluble film formulation of clobazam for treating Lennox-Gastaut syndrome.
• Suboxone: A sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence.
• Zuplenz: An oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
• Azstarys: A once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD).
• Libervant: A proprietary buccal soluble film formulation of diazepam being developed for the treatment of seizures.
• Exservan: A proprietary oral soluble film formulation of riluzole being developed for the treatment of amyotrophic lateral sclerosis (ALS).
• AQST-108: A sublingual film formulation delivering systemic epinephrine in development for conditions other than anaphylaxis.
• AQST-305: A sublingual film formulation of octreotide in development for the treatment of acromegaly.
• AQST-109: An orally delivered epinephrine product candidate in development for the emergency treatment of allergic reactions, including anaphylaxis.
• KYNMOBI: A sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease.

AI Analysis | Feedback

Aquestive Therapeutics (AQST) Major Customers

Aquestive Therapeutics (AQST), as a pharmaceutical company, primarily sells its products to other companies within the healthcare supply chain, rather than directly to individual consumers. Based on the provided background information, specific major customer companies are not identified by name.

However, given the nature of its business (developing and commercializing pharmaceutical products such as Sympazan, Suboxone, Zuplenz, and Azstarys), its customers typically fall into the following categories:

1. Pharmaceutical Wholesalers and Distributors: These companies purchase pharmaceutical products in bulk from manufacturers like Aquestive and distribute them to pharmacies, hospitals, and other healthcare providers across various regions.
2. Retail and Mail-Order Pharmacies: Establishments, including large pharmacy chains and independent pharmacies, that purchase medications to dispense to patients based on prescriptions.
3. Hospitals and Healthcare Systems: Institutions and networks of healthcare facilities that acquire and administer pharmaceutical products for inpatient and outpatient care.

AI Analysis | Feedback

null

AI Analysis | Feedback

Daniel Barber, Chief Executive Officer, President, and Director

Daniel Barber joined Aquestive Therapeutics in July 2007, serving in various roles, and was instrumental in the company's growth, including executive oversight of the launch activities for Aquestive's first two FDA-approved products in 2010. He led strategy and development efforts starting in 2014, became Chief Operating Officer in May 2019, and was appointed Chief Executive Officer and a member of the Board of Directors in May 2022. Before joining Aquestive, Mr. Barber held positions within the corporate planning and international divisions of Quest Diagnostics.

Ernie Toth, Chief Financial Officer

Ernie Toth joined Aquestive Therapeutics as Interim Chief Financial Officer in December 2020 and transitioned to the permanent role of Senior Vice President and Chief Financial Officer in June 2021. Prior to Aquestive, he served as CFO of EHE Health, a health network owned by Summit Partners and DW Healthcare Partners. He was Chief Financial Officer of JHP Pharmaceuticals, a private equity-owned company (Morgan Stanley Private Investments), from 2011 to 2013, where he provided financial leadership through its sale to Warburg Pincus in 2012. Mr. Toth also served as Global Chief Financial Officer of ArisGlobal and Synowledge (which was sold to Bioclinica) and was a member of the Board of Directors of Eska, a Canadian beverage company owned by Morgan Stanley Private Investments, until its sale in 2017. His earlier experience includes 15 years in various financial positions at MacAndrews & Forbes.

Matthew Greenhawt, Chief Medical Officer

Matthew Greenhawt was appointed Chief Medical Officer of Aquestive Therapeutics in February 2026. He is an internationally recognized expert in allergy and immunology, specializing in food allergy, anaphylaxis, patient-centered care, and health services and health policy research.

Matthew Davis, M.D., Chief Development Officer

Matthew Davis joined Aquestive Therapeutics as Chief Development Officer in November 2025. He brings over two decades of experience in drug development and medical leadership from both large pharmaceutical and emerging biotechnology companies. Before joining Aquestive, Dr. Davis served as Chief Medical Officer at Neuvivo, where he was responsible for clinical development and medical strategy in neurological disorders.

Peter Boyd, Chief People Officer

Peter Boyd was promoted to Chief People Officer at Aquestive Therapeutics in November 2025. He joined the company in August 2013 and has been responsible for leading the Information Technology, Human Resources, and Communications functions since December 2022.

AI Analysis | Feedback

Aquestive Therapeutics (NASDAQ: AQST) faces significant business risks primarily stemming from regulatory hurdles for its key pipeline products, coupled with underlying financial instability and intense market competition.

1. Regulatory Setbacks and Delays for Key Pipeline Products

The most immediate and significant risk for Aquestive Therapeutics is the regulatory challenges and delays impacting its lead product candidates, Anaphylm and Libervant. Anaphylm, a sublingual epinephrine film intended for severe allergic reactions, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on January 30, 2026. This CRL cited deficiencies related to human factors validation, specifically concerning pouch opening and film placement, and requested a new pharmacokinetics (PK) study to assess packaging and labeling modifications. This setback delays potential U.S. approval, with a resubmission targeted for Q3 2026. The company considers Anaphylm its "most important growth driver."

Similarly, Libervant, a buccal diazepam film for seizures, has encountered regulatory obstacles. Its U.S. approval for patients aged 2–5 years was vacated by a federal court due to a competitor's orphan-drug exclusivity, leading to tentative approval and a halt in U.S. marketing for this demographic. For patients aged 12 and older, market access for Libervant is blocked until January 2027 due to an existing orphan drug market exclusivity held by another product. These events directly affect what the company describes as its "two most differentiated products."

2. Financial Instability and Funding Risk

Aquestive Therapeutics exhibits signs of financial instability, with projections of a substantial adjusted EBITDA loss for fiscal year 2026, estimated between $30 million and $35 million. The company reported a net loss of $83.8 million for the full year 2025, driven by increased selling, general, and administrative expenses, including significant legal costs. The company's financial health is highly dependent on high-stakes regulatory decisions and involves a considerable cash burn typical of a clinical-stage entity with products in development. While Aquestive raised equity and secured conditional debt financing in 2025, a significant portion of its future funding is contingent upon the FDA approval of Anaphylm, which elevates the company's overall risk profile. Financial indicators such as an Altman Z-Score of -1.55 place the company in a "distress zone," suggesting a potential risk of bankruptcy within two years, and a Piotroski F-Score of 2 indicates poor business operations.

3. Intense Competition

The pharmaceutical market is highly competitive, and Aquestive's products face significant competition. Anaphylm, upon eventual approval, will contend with established epinephrine auto-injectors and other emerging needle-free alternatives. A key competitor, ARS Pharmaceuticals' neffy, an epinephrine nasal spray, has already received FDA approval in the U.S. (2024) and in Europe (August 2024), gaining a head start in the non-injectable epinephrine market. The delays in Anaphylm's approval provide competitors like neffy more time to capture and solidify market share. Additionally, Aquestive's existing revenue from licensed products, such as Suboxone, is facing erosion due to competitive pressures.

AI Analysis | Feedback

AI Analysis | Feedback

Aquestive Therapeutics (AQST) focuses on addressing unmet medical needs with a range of products and product candidates. The addressable markets for their main products are as follows:

• Sympazan (clobazam for Lennox-Gastaut Syndrome): The global Lennox-Gastaut Syndrome (LGS) drug market size was valued at approximately USD 779.89 million in 2024 and is projected to reach USD 1117.60 million by 2032. Another report indicates the LGS market size in the 7MM (United States, EU4, United Kingdom, and Japan) was USD 596 million in 2022 and is anticipated to grow significantly by 2032. The market was also reported at USD 700 million in 2022, with a projection to reach USD 1003.12 million by 2030.
• Suboxone (buprenorphine and naloxone for opioid dependence): The global Suboxone market size was valued at USD 6.78 billion in 2024 and is projected to reach USD 10.38 billion by 2035. Another estimate places the global Suboxone market at approximately USD 3.1 billion in 2022, with a projection to reach roughly USD 6.0 billion by 2030. The broader global Opioid Use Disorder (OUD) market was valued at USD 3.92 billion in 2025 and is projected to grow to USD 9.27 billion by 2034. North America held a significant share of the OUD market, accounting for 77.59% in 2025.
• Zuplenz (ondansetron for nausea and vomiting associated with chemotherapy and post-operative recovery): The global postoperative nausea and vomiting (PONV) treatment market size was valued at USD 2.31 billion in 2024 and is expected to reach USD 3.55 billion by 2032. North America dominated this market with a 39.8% share in 2024. The global antiemetics drugs market, which includes treatments for nausea and vomiting associated with chemotherapy, was valued at USD 7.49 billion in 2023 and is expected to reach USD 7.90 billion in 2024. The chemotherapy-induced nausea and vomiting (CINV) therapeutics market is projected to grow from USD 6.9 billion in 2025 to USD 13.0 billion by 2035 globally.
• Azstarys (once-daily product for the treatment of attention deficit hyperactivity disorder): The global Attention-Deficit Hyperactivity Disorder (ADHD) therapeutics market was valued at USD 9.6 billion in 2023 and is expected to reach USD 13.6 billion by 2034. This market is projected to reach approximately USD 20 billion by 2026. The global ADHD treatment market was valued at US$ 11.0 billion in 2023 and is expected to reach US$ 15.4 billion by the end of 2034.
• Libervant (buccal soluble film formulation of diazepam for the treatment of seizures): The global epileptic seizures treatment market size was USD 3.42 billion in 2024 and is projected to reach USD 4.72 billion in 2029. Another estimate indicates the global epileptic seizures treatment market size will be USD 12,560 million in 2025, with North America holding over 37% (USD 4,647.20 million) in 2025. The global epilepsy treatment drugs market was estimated at USD 8.3 billion in 2024 and is expected to grow to USD 13 billion by 2034. North America dominated this market with a 41% share in 2024.
• Exservan (oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis): The Amyotrophic Lateral Sclerosis (ALS) treatment market size in the 7MM (United States, EU4, United Kingdom, and Japan) was around USD 1,000 million in 2023. The global amyotrophic lateral sclerosis treatment market size was estimated at USD 667.3 million in 2023 and is projected to reach USD 987.6 million by 2030. North America dominated the global ALS treatment market with a revenue share of 37.7% in 2023. The ALS treatment market size was valued at USD 726.62 million in 2024, with North America holding the largest revenue share of 44.2% in 2024, and the U.S. accounting for 77% within North America.
• AQST-108 and AQST-109 (epinephrine for allergic reactions, including anaphylaxis): The global epinephrine for anaphylaxis treatment market size was valued at USD 1.80 billion in 2025 and is projected to grow to USD 4.10 billion by 2034. North America dominated this market with a 67.23% share in 2025, and the U.S. market alone was valued at USD 1.28 billion by 2026. The broader global epinephrine market size was approximately USD 3.30 billion in 2025 and is predicted to increase to USD 6.87 billion by 2034. North America acquired a major revenue share of 33.45% in 2024 within the global epinephrine market.
• AQST-305 (sublingual film formulation of octreotide for the treatment of acromegaly): The global acromegaly treatment market size was valued at USD 2.2 billion in 2023 and is estimated to grow. The U.S. acromegaly treatment market size was USD 876.4 million in 2023. Another source states the global acromegaly treatment market size was USD 1.77 billion in 2025 and is projected to grow to USD 3.13 billion by 2034. North America holds approximately 35% of the global acromegaly treatment market share. The Acromegaly market in the 7MM was around USD 1,300 million in 2023, with the United States accounting for approximately USD 700 million.
• KYNMOBI (sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease): null

AI Analysis | Feedback

Aquestive Therapeutics (NASDAQ: AQST) anticipates several key drivers for its future revenue growth over the next two to three years, primarily centered around the commercialization of its proprietary product candidates and continued growth from existing manufacturing and supply agreements.

1. Launch and Commercialization of Anaphylm: The primary expected driver of future revenue growth is the potential approval and subsequent launch of Anaphylm (dibutepinephrine) Sublingual Film, an orally delivered epinephrine product for the emergency treatment of allergic reactions, including anaphylaxis. Aquestive aims to resubmit its New Drug Application (NDA) for Anaphylm to the FDA in Q3 2026, with a potential approval in early 2027. The company plans to significantly scale its commercial preparations, including increasing its sales force to 75 representatives upon approval and expanding its medical affairs team to raise physician awareness. Additionally, Aquestive is pursuing international expansion for Anaphylm, with regulatory applications planned for Canada and the European Union in 2026. Analysts have estimated peak sales for Anaphylm to be between $300 million and $400 million.

2. Out-licensing of Libervant: Aquestive Therapeutics is actively pursuing out-licensing opportunities for Libervant (diazepam buccal film) in the U.S. for the treatment of seizures. This strategic decision is influenced by the company's prioritization of Anaphylm's launch. Libervant has already received FDA approval for certain pediatric epilepsy patients aged two to five years and holds Orphan Drug Exclusivity (ODE) until 2031 for this age group, which could provide a stable revenue stream through upfront payments and/or royalty agreements.

3. Growth in Manufacturing and Supply Revenue: Aquestive continues to generate revenue from its manufacturing and supply agreements for commercialized products like Suboxone (buprenorphine and naloxone), Ondif (ondansetron), Sympazan (clobazam), and Emylif (riluzole). The company reported a 10% year-over-year increase in total revenue in Q4 2025, primarily driven by growth in manufacturing and supply revenue from Suboxone and Ondif. This established revenue stream is expected to continue contributing to overall financial performance as the company advances its pipeline.

4. Advancement and Potential Commercialization of AQST-108: The development of AQST-108, a topical epinephrine gel for the treatment of alopecia areata, represents another potential long-term revenue driver. The company has opened an Investigational New Drug (IND) application for AQST-108 and is conducting a Phase 1 clinical trial, with top-line data anticipated in the near future. This product candidate targets a significant market, potentially worth over a billion dollars, and successful development could lead to a valuable asset for future commercialization or partnerships.

AI Analysis | Feedback

Capital Allocation Decisions (Last 3-5 Years)

Share Issuance

• Aquestive Therapeutics entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC in April 2022, providing the right to sell up to $40 million worth of shares of its common stock over 36 months at the company's discretion.
• In June 2022, the company completed a registered direct offering of common stock and warrants, generating gross proceeds of approximately $8.5 million.
• In March 2024, Aquestive priced an underwritten public offering of 16,666,667 shares of common stock at $4.50 per share, with expected gross proceeds of approximately $75.0 million.

Inbound Investments

• Aquestive secured a $75 million strategic funding agreement with RTW Investments, LP in August 2025, contingent on FDA approval of Anaphylm, intended to support the company through 2027 for a potential commercial launch.
• RTW Investments, LP also agreed to an additional strategic investment of $5 million in Aquestive, as reported in March 2026.
• Institutional investors, including Aberdeen Group plc, Commonwealth Equity Services LLC, and Federated Hermes Inc., acquired or increased their stakes in Aquestive Therapeutics in 2025 and 2026.

Capital Expenditures

• Aquestive Therapeutics' historical capital expenditures were $1 million in 2021, $3 million in 2022, $1 million in 2023, and $0 million in 2024.
• In Q4 2025, the company invested $85K in capital expenditures.
• Projected capital expenditures are $1 million annually from 2025 through 2029.